MDS
Myelodysplastic syndromes (MDS) are diseases of the blood cells and bone marrow. MDS are a collection of myeloid malignancies characterized by one or more peripheral blood cytopenias. Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
Advertisement
Advertisement
This new indication for the injection alkylating agent pertains to adult or pediatric patients aged one year and older.
The COMMANDS trial evaluated frontline luspatercept in transfusion-dependent patients with lower-risk MDS and anemia.
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
HMAs, either as monotherapy or in combination with venetoclax, represent the standard of care for higher-risk MDS or AML.
According to a study, patients with MDS and CMML have dismal clinical outcomes after failure of HMA therapy.
Investigational combinations for MDS appeared to be well tolerated while triplets results in high-grade toxicity.
An expert speaks on site at ASH 2024 about the health-related quality of life data from the phase 3 COMMANDS trial.
Phase 2 study results outline benefit of adding venetoclax to intensive chemo in MDS and AML patients.
Moving forward, prospective studies must validate these findings and refine risk stratification tools like the IPSS-R in MDS.
Some patients with ZRSR2-mutated CCUS had concurrent blood cancers or disorders, and others had protective co-mutation.
A discussion on the post hoc analysis on quality of life from the COMMANDS trial.
Discussing the COMMANDS trial and sequencing luspatercept in patients with myelodysplastic syndromes.
How to address ESA failure or ineligibility in patients with MDS...
Results from a real-world analysis of post-ESA treatment outcomes in patients with lower-risk myelodysplastic syndrome.
Early signs of clinical activity have been shown in a phase I/II study of tagraxofusp/decitabine in MDS and CMML.
Mature data of three immunotherapy-based hypomethylating agent combinations were presented at ASH.
High complete response rates and low early mortality rates facilitate the majority of patients to allogeneic SCT.
An ongoing phase 1 study is evaluating the safety and efficacy of danvatirsen through two substudies.
New WHO and ICC 022 guidelines propose lowering the threshold for diagnosis of CMML.
High-risk MDS is associated with poor outcomes, making the assessment of treatment response critical.
A myelofibrosis cohort showed that tapering to achieve molecular remission helped promote OS after transplant.
The design of a phase 3 trial of elritercept for transfusion-dependent anemia in lower-risk MDS was presented at ASH 2024.
Increasing evidence suggests a connection between acquired somatic mutations and inflammatory processes in myeloid neoplasms.
The clinical activity of vibecotamab in low-blast, high-risk myeloid neoplasms has been demonstrated in a phase II study.
Somatic IDH1 mutations are present in approximately 3% of patients with MDS and are associated with poor prognosis.
New research is offering new hope for these challenging case of MDS and sAML.
Ivosidenib is a promising oral therapy for patients with IDH1-mutated MDS.
Overall survival is improved in patients with SF3B1del5q-mutated MDS when lenalidomide is sequenced before luspatercept.
Findings from a phase II trial study of patients with MDS highlight the clinical benefits and safety profile of enasidenib.
Ceralasertib is a novel oral ataxia telangiectasia and Rad3-related inhibitor for patients with myelodysplastic syndromes.
The presence of genetic mutations and specific cytopenias emerged as key predictors of progression in MDS.
The phase 3 COMMANDS trial results underscore the potential longer-term clinical benefits of luspatercept in lower-risk MDS.
Phase 2 results of AZA-VEN in acute myeloid leukemia shows an efficacy benefit.
New findings underscore the potential of single-cell analyses in the unbiased unraveling of disease mechanisms in MDS.
Results from the phase 1 Combala study show the benefit of luspatercept and erythropoiesis-stimulating agents in MDS.
The phase 3 EPO-PRETAR trial demonstrates importance of early administration of ESAs in patients with MDS and anemia.
Tapotoclax was safe and may warrant consideration in combination with other therapies in MDS post-HMA failure.
ESAs had a high rate of failure among patients with lower-risk MDS and often continued treatment despite failure.
Oral azacitidine plus cedazuridine achieved pharmacokinetic equivalence to subcutaneous azacitidine in MDS and MPN.
Retrospective analysis shows that AML treatment strategies are effective for patients with MDS or CMML with NPM1 mutations.
This type of intervention produced more favorable results in patients with either hematologic or pre-hematologic relapse.
High circular RNA abundance is correlated with disease progression in patients with MDS.
The favorable effects from vamifeport pharmacologic iron restriction were enhanced by combination with luspatercept.
The model's superior engrafting of HSPCs from patients with MDS brings better replication of the disease microenvironment.
In this roundtable segment, the panel discussed imetelstat for the treatment of lower-risk MDS.
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss which patients with MDS should be treated with luspatercept.
Is ESA use and performance in the academic setting reflective of real-world MDS practice? Our expert panel discusses.
The panel discusses how to best implement such a monitoring system to address a widespread issue of suboptimal dosing.
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss dosing considerations for luspatercept for lower-risk MDS.
The panel discussed the four COMMANDS trial abstracts on luspatercept for lower-risk MDS presented at EHA 2024.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters: